Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 2,720,000 shares, a decrease of 15.5% from the January 15th total of 3,220,000 shares. Based on an average daily volume of 477,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 24.2% of the company's stock are short sold.

Analyst Ratings Changes

Several analysts recently commented on the stock. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada dropped their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a report on Thursday, January 9th. UBS Group started coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $38.00 price target on the stock. Finally, HC Wainwright dropped their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $64.44.

Hedge Funds Weigh In On Jasper Therapeutics

Several institutional investors have recently made changes to their positions in JSPR. BNP Paribas Financial Markets lifted its stake in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock worth $47,000 after purchasing an additional 1,698 shares during the period. MetLife Investment Management LLC raised its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after acquiring an additional 3,873 shares during the period. Wells Fargo & Company MN raised its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC bought a new stake in Jasper Therapeutics during the 4th quarter worth approximately $223,000. Finally, Jane Street Group LLC bought a new stake in Jasper Therapeutics during the 3rd quarter worth approximately $251,000. Institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR traded down $0.09 during trading on Thursday, hitting $6.16. The company's stock had a trading volume of 162,397 shares, compared to its average volume of 777,639. The company has a 50-day moving average of $11.81 and a 200-day moving average of $17.28. Jasper Therapeutics has a 12 month low of $4.55 and a 12 month high of $31.01. The firm has a market cap of $92.40 million, a price-to-earnings ratio of -1.30 and a beta of 2.11.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.